PTGX logo

Protagonist Therapeutics (PTGX)

Profile

Full Name

Protagonist Therapeutics, Inc.

Ticker Symbol

PTGX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

August 11, 2016

Indexes

Not included

Website

http://www.protagonist-inc.com

Employees

126

Key Details

Price

$42.62(+4.23%)

Market cap

$2.62B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$434.43M(+624.06% YoY)

Annual EPS

$4.23(+404.32% YoY)

PE ratio

10.15

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$42.62
PTGX price is $42.62

30-Day Relative Volume

0.72
PTGX 30-day relative volume is 0.72

Price Performance

Price Today change

+4.23%
PTGX price is up +4.23% today

Price YTD change

+10.41%
PTGX price is up +10.41% since January 1st

Price 1-year change

+54.09%
PTGX price is up +54.09% year-on-year

Price 3-year change

+77.14%
PTGX price is up +77.14% over the past 3 years

Price Range

Price All-time high

$60.60
PTGX price is currently -29.67% below its historical high of $60.60

Price 3-year low

$6.91
PTGX price is currently +516.79% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$2.62B
PTGX market capitalization is $2.62 billion

Market cap 3-year change

+123.96%
PTGX market capitalization is up +123.96% over the past 3 years

Market cap All-time high

$3.65B
PTGX market capitalization is currently -28.37% below its historical high of $3.65 billion

Market cap sector rank

85.21%
PTGX market capitalization is higher than 85.21% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+4.75%
PTGX shares outstanding is up +4.75% year-on-year

Shares Outstanding 3-Year Change

+26.43%
PTGX shares outstanding is up +26.43% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.29
PTGX beta is 0.29

200-day SMA

$41.93
PTGX price is currently +1.65% above its 200-day simple moving average

50-day SMA

$43.85
PTGX price is currently -2.81% below its 50-day simple moving average

RSI

41.30
PTGX 14-day relative strength index is 41.30

Volume

0.72
PTGX 30-day relative volume is 0.72

ATR

$2.74
PTGX average true range is $2.74

10-day Historical Volatility

50.68%
PTGX 10-day historical volatility is 50.68%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$434.43M
PTGX annual revenue is $434.43 million

Revenue Analysts estimate

$98.78M
PTGX annual revenue is currently +339.80% higher than the consensus analysts' forecast

Revenue 1-year change

+624.06%
PTGX annual revenue is up +624.06% year-on-year

Revenue Sector rank

72.68%
PTGX annual revenue is higher than 72.68% of companies in Healthcare sector

EPS

EPS

$4.23
PTGX annual earnings per share is $4.23

EPS Analysts estimate

-$1.23
PTGX annual earnings per share is currently -444.97% lower than the consensus analysts' forecast

EPS 1-year change

+404.32%
PTGX annual earnings per share is up +404.32% year-on-year

EPS Sector rank

94.96%
PTGX annual earnings per share is higher than 94.96% of companies in Healthcare sector

Profit

Gross profit

-
PTGX annual gross profit value is unknown

Gross margin

-
PTGX annual gross profit margin value is unknown

Operating profit

$252.84M
PTGX annual operating income is $252.84 million

Operating margin

58.20%
PTGX annual operating profit margin is 58.20%

Net income

$275.19M
PTGX annual net profit is $275.19 million

Net margin

63.34%
PTGX annual net profit margin is 63.34%

Expenses

Total expenses

$181.59M
PTGX annual total expenses is $181.59 million

Operating expenses

$181.59M
PTGX annual total operating expenses is $181.59 million

Cost of goods sold

-
PTGX annual cost of goods sold value is unknown

Selling, general & administrative expenses

$43.46M
PTGX annual SGA is $43.46 million

Depreciation and amortization

$2.90M
PTGX annual depreciation & amortization is $2.90 million

Interest expense

-
PTGX annual interest expense value is unknown

Income tax

$4.22M
PTGX annual income tax is $4.22 million

EBIT & EBITDA

EBIT

$252.84M
PTGX annual earnings before interest & taxes is $252.84 million

EBITDA

$255.74M
PTGX annual EBITDA is $255.74 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$744.73M
PTGX annual total assets is $744.73 million

Non current assets

$153.08M
PTGX annual long term assets is $153.08 million

Current assets

$591.64M
PTGX annual total current assets is $591.64 million

Cash and cash equivalents

$97.25M
PTGX annual cash & cash equivalents is $97.25 million

Accounts receivable

-
PTGX annual accounts receivable value is unknown

Inventory

-
PTGX annual inventory value is unknown

Liabilities

Total liabilities

$69.43M
PTGX annual total liabilities is $69.43 million

Long term liabilities

$22.03M
PTGX annual total long term liabilities is $22.03 million

Current liabilities

$47.40M
PTGX annual total current liabilities is $47.40 million

Accounts payable

$1.61M
PTGX annual accounts payable is $1.61 million

Debt

Total debt

$10.87M
PTGX annual total debt is $10.87 million

Total debt 1-year change

+852.32%
PTGX annual total debt is up +852.32% year-on-year

Long term debt

$10.36M
PTGX annual long term debt is $10.36 million

Short term debt

$510.00K
PTGX annual short term debt is $510.00 thousand

Equity & Capital

Shareholders equity

$675.29M
PTGX annual stockholders equity is $675.29 million

Book value

$675.29M
PTGX annual book value is $675.29 million

Retained earnings

-$340.52M
PTGX annual retained earnings is -$340.52 million

Working capital

$544.24M
PTGX annual working capital is $544.24 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$184.15M
PTGX annual cash flow from operations is $184.15 million

Cash from operations 1-year change

+362.19%
PTGX annual cash flow from operations is up +362.19% year-on-year

Cash from investing

-$299.48M
PTGX annual cash flow from investing activities is -$299.48 million

Cash from investing 1-year change

-662.86%
PTGX annual cash flow from investing activities is down -662.86% year-on-year

Cash from financing

$25.85M
PTGX annual cash flow from financing activities is $25.85 million

Cash from financing 1-year change

-84.83%
PTGX annual cash flow from financing activities is down -84.83% year-on-year

CAPEX

CAPEX

$1.35M
PTGX annual capital expenditures is $1.35 million

CAPEX 1-year change

+122.5%
PTGX annual capital expenditures is up +122.5% year-on-year

Free Cash Flow

Free cash flow

$182.80M
PTGX annual free cash flow is $182.80 million

Free cash flow 1-year change

+358.02%
PTGX annual free cash flow is up +358.02% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
PTGX annual gross profit margin value is unknown

Operating margin

58.20%
PTGX annual operating profit margin is 58.20%

Net margin

63.34%
PTGX annual net profit margin is 63.34%

ROA & ROE

ROA

49.91%
PTGX annual return on assets is 49.91%

ROE

54.39%
PTGX annual return on equity is 54.39%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

10.15
PTGX price to earnings ratio is 10.15

PE ratio Sector rank

13.3%
PTGX price to earnings ratio is higher than 13.3% of companies in Healthcare sector

PB Ratio

PB ratio

3.87
PTGX price to book ratio is 3.87

PB ratio Sector rank

78.7%
PTGX price to book ratio is higher than 78.7% of companies in Healthcare sector

PS Ratio

PS ratio

6.02
PTGX price to sales ratio is 6.02

PS ratio Sector rank

70.64%
PTGX price to sales ratio is higher than 70.64% of companies in Healthcare sector

Enterprise value

Enterprise value

$2.53B
PTGX enterprise value is $2.53 billion

Enterprise value Sector rank

84.17%
PTGX enterprise value is higher than 84.17% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

9.89
PTGX EV/EBITDA is 9.89

EV/EBITDA Sector rank

82.47%
PTGX EV/EBITDA is higher than 82.47% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

12.48
PTGX annual current ratio is 12.48

Quick ratio

-
PTGX annual quick ratio value is unknown

Leverage

Debt to equity

0.00
PTGX annual debt to equity ratio is 0.00

Interest coverage ratio

-
PTGX annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
PTGX piotroski f-score value is unknown

Altman Z-Score

24.55
PTGX altman z-score is 24.55

Analyst ratings

Recent major analysts updates

Apr 10, 25 HC Wainwright & Co.
Buy
Mar 28, 25 Wedbush
Outperform
Mar 11, 25 Truist Securities
Buy
Mar 11, 25 HC Wainwright & Co.
Buy
Mar 11, 25 BMO Capital
Outperform
Mar 10, 25 HC Wainwright & Co.
Buy
Mar 10, 25 Citizens Capital Markets
Market Outperform
Mar 4, 25 JP Morgan
Overweight
Mar 3, 25 HC Wainwright & Co.
Buy
Feb 24, 25 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

IMVT logo
Immunovant (IMVT)
ACHC logo
Acadia Healthcare (ACHC)
XRAY logo
DENTSPLY SIRONA (XRAY)
CRNX logo
Crinetics Pharmaceuticals (CRNX)
SRRK logo
Scholar Rock Holding (SRRK)
ALVO logo
Alvotech (ALVO)
TMDX logo
TransMedics (TMDX)
SWTX logo
SpringWorks Therapeutics (SWTX)
GeneDx Holdings (WGS)
  • What is the ticker symbol for Protagonist Therapeutics?
  • Does Protagonist Therapeutics pay dividends?
  • What sector is Protagonist Therapeutics in?
  • What industry is Protagonist Therapeutics in?
  • What country is Protagonist Therapeutics based in?
  • When did Protagonist Therapeutics go public?
  • Is Protagonist Therapeutics in the S&P 500?
  • Is Protagonist Therapeutics in the NASDAQ 100?
  • Is Protagonist Therapeutics in the Dow Jones?
  • When was Protagonist Therapeutics's last earnings report?
  • When does Protagonist Therapeutics report earnings?
  • Should I buy Protagonist Therapeutics stock now?

What is the ticker symbol for Protagonist Therapeutics?

The ticker symbol for Protagonist Therapeutics is NASDAQ:PTGX

Does Protagonist Therapeutics pay dividends?

No, Protagonist Therapeutics does not pay dividends

What sector is Protagonist Therapeutics in?

Protagonist Therapeutics is in the Healthcare sector

What industry is Protagonist Therapeutics in?

Protagonist Therapeutics is in the Biotechnology industry

What country is Protagonist Therapeutics based in?

Protagonist Therapeutics is headquartered in United States

When did Protagonist Therapeutics go public?

Protagonist Therapeutics's initial public offering (IPO) was on August 11, 2016

Is Protagonist Therapeutics in the S&P 500?

No, Protagonist Therapeutics is not included in the S&P 500 index

Is Protagonist Therapeutics in the NASDAQ 100?

No, Protagonist Therapeutics is not included in the NASDAQ 100 index

Is Protagonist Therapeutics in the Dow Jones?

No, Protagonist Therapeutics is not included in the Dow Jones index

When was Protagonist Therapeutics's last earnings report?

Protagonist Therapeutics's most recent earnings report was on Feb 21, 2025

When does Protagonist Therapeutics report earnings?

The next expected earnings date for Protagonist Therapeutics is May 7, 2025

Should I buy Protagonist Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page